GlassScriptPhysician profile
Takeya Renee Fogle
NPI 1306351911
$1,047.71
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $318 · 2022: $326 · 2023: $335 · 2024: $69.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $404.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $403.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $303.99 | 2021-2023 | |
| Novo Nordisk INC | $201.59 | 2021-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $86.83 | 2021-2023 | Jardiance |
| Amgen INC. | $76.40 | 2021-2022 | |
| Abbott Laboratories | $40.96 | 2022-2024 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $39.20 | 2022-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $37.04 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.44 | 2022 | |
| Sumitomo Pharma America, INC. | $28.39 | 2023 | Gemtesa |
| Pfizer INC. | $27.02 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.93 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $19.61 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.53 | 2021 | |
| Neos Therapeutics, LP | $18.31 | 2024 | Adzenys Xr-Odt |
| Glaxosmithkline, LLC. | $18.30 | 2023 | Shingrix, Trelegy Ellipta, Arexvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $17.13 | 2022 | |
| Esperion Therapeutics, INC. | $15.82 | 2021 | |
| Amarin Pharma, INC. | $15.80 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.01 | 2022 | |
| Astellas Pharma US INC | $11.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Takeya Fogle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.